Growth & Expansion Celogics is expanding its facilities and capabilities in biomanufacturing for iPSC-derived cells, signaling a growing demand for specialized cell culture services and scalable production partnerships that sales teams can target with contract manufacturing, sourcing, and collaboration opportunities.

Strategic Partnership As a joint venture between Curi Bio and NEXEL, Celogics has established strong industry ties and credibility which can be leveraged to pursue co-development deals, technology licensing, and joint-funded research programs with pharma and biotech customers.

Target Market The focus on drug discovery, safety screening, and disease modeling using iPSC-derived cells identifies pharma, biotech, and academic research labs as primary customers for high-quality functional cells and related research services.

Budget & Opportunity Current revenue range and the advancing facility build-out indicate a growing spend profile among target buyers for CRO/CMO services, cell products, and custom cell model development, presenting multiple upsell and multi-year engagement opportunities.

Digital & Ops Readiness Existing tech stack and cloud-based infrastructure suggest readiness for online product catalog, eCommerce ordering, and customer portal integrations, enabling streamlined procurement, trial orders, and scalable customer support.